Coronavirus Notebook: US FDA's Paper Push, Industry Execs/US Officials Emphasize Their Collaboration
Executive Summary
Dispatches from a world turned upside down include the US FDA expressing confidence in Chinese manufacturers – to make their GDUFA payments; projections of drug shortages for ventilator patients; and the launch of new hydroxychloroquine studies.
You may also be interested in...
Taking The ‘O’ Out Of RTOR: US FDA’s Real-Time Review Primed For Expansion Beyond Oncology
Technology modernization efforts, the expansion of cloud-based submission capabilities, and the ongoing COVID-19 pandemic could serve as catalysts to broaden FDA’s Real-Time Oncology Review program beyond cancer therapeutics, Pfizer exec Richard Jahn says.
US FDA Waives Warning Cap Requirement For Neuromuscular Agents As Demand Outranks Safety Worries
COVID-driven supply shortages were both the cause of and solution to production deficiencies for manufacturers of neuromuscular blocking agents; US FDA is permitting Mylan, Gland, and Fresenius Kabi to distribute vecuronium bromide and rocuronium bromide even though they do not have the ‘paralyzing agent’ warning on the caps since the products are in high demand at ICUs. The appropriately embossed caps were unavailable due to supply chain disruptions caused by the pandemic.
Trump’s Rhetorical Pivot On Pharma: The Hucksterism Is Still A Threat
It is nice for pharma CEOs to be called ‘brilliant’ by a President who once said they are ‘getting away with murder.’ But the ‘new’ Trump rhetoric still has major pitfalls for industry – including a fundamental risk of undermining regulatory standards.